Role of Interferon-gamma in Interleukin 12-induced Pathology in Mice
Overview
Authors
Affiliations
Interleukin 12 (IL-12) activates natural killer (NK) and T cells with the secondary synthesis and release of interferon-gamma (IFN-gamma) and other cytokines. IL-12-induced organ alterations are reported for mice and the pathogenetic role of IFN-gamma is investigated by the use of mice deficient in the IFN-gamma receptor (IFN-gamma R-/-). IL-12 caused a rapid infiltration of liver and splenic red pulp with activated macrophages; this and increased NK cells resulted in a fivefold increase of splenic weight in wild-type mice. Splenomegaly was associated with myelosuppression and decreasing peripheral leukocyte counts. IL-12-induced changes in wild-type mice were associated with markedly increased IFN-gamma serum levels and up-regulation of major histocompatibility complex (MHC) class I and II expression in various epithelia. IL-12 induced a qualitatively similar macrophage infiltration in IFN-gamma R-/- mice, less marked splenomegaly (to 2 x normal), and no MHC upregulation. Strikingly increased vascular endothelial intercellular adhesion molecule-1 expression was apparent in both IFN-gamma R-/- and IFN-gamma R+/+ mice. Restricted to mutant mice was a severe, invariably lethal, interstitial, and perivascular pulmonary macrophage infiltration with diffuse pulmonary edema. Extensive quantitative reverse transcriptase polymerase chain reaction analysis revealed an increase of only IL-6 and IL-10 pulmonary gene transcripts in IFN-gamma R-/- mice compared with wild-type mice. IL-12-induced myelosuppression is due to IFN-gamma-release from NK cells and T cells, and is associated with macrophage activation and distinct MHC class I and II antigen upregulation. The pulmonary pathology in IFN-gamma R-/- mice, however, reveals a toxic potential for IL-12 and suggests that endogenous IFN-gamma plays a protective role in preventing fatal pulmonary disease in these mice.
Chen F, Wu K, Lin S, Cui J, Chen X, Zeng Z Antibodies (Basel). 2024; 13(4).
PMID: 39584994 PMC: 11586976. DOI: 10.3390/antib13040094.
Valenzuela-Cardenas M, Fisher C, Bartee M, Bartee E Mol Ther Oncol. 2024; 32(3):200866.
PMID: 39290317 PMC: 11407086. DOI: 10.1016/j.omton.2024.200866.
Boersma B, Poinot H, Pommier A Pharmaceutics. 2024; 16(8).
PMID: 39204319 PMC: 11357675. DOI: 10.3390/pharmaceutics16080974.
"Target-and-release" nanoparticles for effective immunotherapy of metastatic ovarian cancer.
Pires I, Covarrubias G, Gomerdinger V, Backlund C, Shanker A, Gordon E bioRxiv. 2024; .
PMID: 39005274 PMC: 11245112. DOI: 10.1101/2024.07.05.602135.
Zou Z, Shen J, Xue D, Li H, Xu L, Cao W Nat Commun. 2024; 15(1):4701.
PMID: 38830882 PMC: 11148143. DOI: 10.1038/s41467-024-49034-1.